Defactinib, also known as VS-6063 and PF04554878, is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Defactinib |
| Iupac 化学名称 | 1073160-26-5 |
| 同义词 | Defactinib hydrochloride; Defactinib HCl; VS6063; VS 6063; VS-6063; PF04554878; PF-04554878; PF 04554878; PF4554878; PF-4554878; PF4554878 |
| 英文同义词 | Defactinib hydrochloride; Defactinib HCl; VS6063; VS 6063; VS-6063; PF04554878; PF-04554878; PF 04554878; PF4554878; PF-4554878; PF4554878 |
| 分子式 | C20H22ClF3N8O3S |
| 分子量 | 546.9542 |
| InChiKey | |
| InChi | |
| Cas号 | 1073160-26-5 |
| 相关CAS号 | |
| 外观性状 | crystalline solid |
| 纯度 | 98% |
| 存储 | 3 years -20ºCpowder |
| 可溶性 | Soluble in DMSO |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature as non-hazardous chemical. |
| 海关编码 | |
| Targets | |
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study | |